Physician profile

Wendell R Miers

Endocrinology, Diabetes & Metabolism · Lexington, KY

NPI 1356403489

$38,241.33

in general payments reported to CMS, 2019-2025

51 companies · $808 in 2025

The $808 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

See the full distribution for Endocrinology, Diabetes & Metabolism

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,999.78
Education$90.00
Long Term Medical Supply Or Device Loan$49.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $24,870.08 2019-2025 Ozempic, Rybelsus, Wegovy
Janssen Pharmaceuticals, INC $4,427.96 2019
Boehringer Ingelheim Pharmaceuticals, INC. $744.73 2019-2023 Jardiance
Dexcom, INC. $721.85 2019-2024 Dexcom G6 Transmitter
Mannkind Corporation $692.87 2019-2025 Afrezza
Abbott Laboratories $661.85 2019-2025 Freestyle Libre 3, Freestyle Insulinx
Astrazeneca Pharmaceuticals LP $660.03 2019-2023 Farxiga
Bayer Healthcare Pharmaceuticals INC. $595.07 2021-2025
Medtronic, INC. $584.93 2021-2025 Minimed 780g, Minimed 770g
Sanofi-Aventis U.S. LLC $433.76 2019-2023
Amarin Pharma, INC. $431.50 2019-2021
Lilly USA, LLC $308.71 2019-2023 Mounjaro, Jardiance
Abbvie INC. $295.75 2019-2023
Insulet Corporation $238.99 2020-2025 Omnipod
Tandem Diabetes Care, INC. $236.46 2019-2025 T:Slim X2 Insulin Pump With Control-Iq
Show all 48 companies
CompanyGeneral paymentsYearsTop products
Xeris Pharmaceuticals, INC. $227.98 2020-2023 Gvoke Hypopen
Antares Pharma, INC. $196.17 2019-2023 Nocdurna, Xyosted, Tlando
Merck Sharp & Dohme LLC $194.51 2019-2020
Corcept Therapeutics $184.04 2019-2024 Korlym
Amgen INC. $145.30 2019-2025 Repatha, Repatha
Esperion Therapeutics, INC. $140.00 2020-2021
Zealand Pharma US, INC. $125.74 2020-2022
Ascendis Pharma Endocrinology INC $120.16 2023-2025 Yorvipath
Horizon Therapeutics Plc $101.54 2019-2023 Tepezza
Becton, Dickinson and Company $93.50 2019-2022
Alexion Pharmaceuticals, INC. $72.41 2021-2023 Strensiq
Radius Health, INC. $69.46 2021
Amryt Pharma Holdings LTD $69.19 2021-2023 Mycapssa
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $59.29 2019-2021
Amneal Pharmaceuticals LLC $55.71 2019-2025 Crexont
Ibsa Pharma INC. $55.17 2019-2022
Tolmar, INC. $47.50 2023
Beta Bionics, INC. $43.92 2025 Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach
Halozyme INC $43.33 2023
Takeda Pharmaceuticals U.S.A., INC. $37.90 2020
Shire North American Group INC $31.90 2019
Sequel Med Tech, LLC $29.58 2025 Twiist
Almatica Pharma LLC $25.94 2025 Loreev Xr
Medtronic Minimed, INC. $23.74 2019
Senseonics, Incorporated $21.00 2019
Neurocrine Biosciences, INC. $20.94 2025
Lifescan, INC. $18.62 2022
Kyowa Kirin, INC. $17.19 2025
Recordati_rare_diseases_inc. $15.55 2023 Isturisa
Azurity Pharmaceuticals, INC. $15.42 2023 Adthyza
Ultragenyx Pharmaceutical INC. $15.26 2023
Kowa Pharmaceuticals America, INC. $11.94 2021
Advanced Oxygen Therapy INC. $6.89 2025 Topical Oxygen Chamber For Extremities

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$9,436.68 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Wendell R Miers

$38,241.33

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk INC
Context
The $808 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

https://glasscript.com/doctor/106486/wendell-r-miers

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.